The ROCKET study is a clinical research study that will help determine if an investigational medicine, called OV101 or gaboxadol, is safe and effective in treating behavioral characteristics commonly present in people with Fragile X syndrome (FXS). The study will test three different doses of OV101.

Participation in the ROCKET study will last approximately 21 weeks and include six visits to the study medical center and four phone appointments. The study center visits will last the majority of the day.

At the clinic appointments, you will meet with your study team, which will include a study physician, nurse, and other healthcare professionals. They will explain the study, answer your questions, and monitor your care.

The phone appointments will take place between visits to the study medical center. During these calls, a study team member will ask about any changes in your son’s health and behavior. You may also discuss any side effects or new symptoms your son may be experiencing and any new medicines or vitamins he may be taking.

Eligibility

Sex: Male
Age: 13 to 22
Disorder: Confirmed diagnosis of Fragile X syndrome

He also needs to be able to swallow a capsule, or its contents when mixed with soft food; and must have a parent or caregiver who can provide consent, attend scheduled visits, and participate in study assessments and scheduled phone meetings.

U.S. Locations

  • Phoenix, Arizona
  • Sacramento, California
  • Aurora, Colorado
  • Chicago, Illinois
  • Baltimore, Maryland
  • Cincinnati, Ohio
  • Media, Pennsylvania
  • Nashville, Tennessee

Frequently Asked Questions

A clinical research study is a scientific test that helps determine if and how a potential medicine or treatment may work. Clinical research studies, like the ROCKET study, are monitored by the U.S. Food and Drug Administration and reviewed by independent ethics committees to safeguard the rights and welfare of research participants.

People agree to participate in studies for many reasons, including the chance to help others who may be or become affected by certain conditions, give back to the scientific community, play an active role in their health and gain access to new potential medicines.

No. Participating in any clinical study is completely voluntary.

Deciding to volunteer in a study is an important choice. If your son qualifies to participate in the ROCKET study, your study team will ensure that both of you understand the study and its possible risks and benefits. You or your son can decide to withdraw from the ROCKET study at any time.

No. You will not be charged for taking part in the study. The investigational medicine and care required by the study will be provided at no expense by the study sponsor, Ovid Therapeutics™. You will also be reimbursed for travel-related expenses, and travel can be arranged for you. Please talk with your study team for more information.

Contact

Luke Rosen
Director of Patient Engagement
646-930-4387
lrosen@ovidrx.com

Study Director
Amit Rakhit, M.D.

Sponsor
Ovid Therapeutics Inc.

Clinicaltrials.gov Identifier:
NCT03697161

If you’d like to learn more or apply for this opportunity, please fill out the form to send your contact information to the study coordinators.



Our Most Recent Opportunities
If you arrived on this page through a MyFXResearch Portal search, you can close this window and return to your filtered results. Or start a new search here.

Survey: Cannabidiol (CBD) Use with Fragile X Syndrome

A Mount Sinai Genetic Counseling graduate student is conducting a research study to learn about possible benefits and side effects of CBD supplements when used to treat FXS symptoms. This information will be obtained by using an anonymous online parental and caregiver survey.  About the Survey Who can participate? Parents and caregivers caring for somebody with FXS who uses, or has used, CBD supplements may be eligible to participate. The parent or caregiver responding to the survey must be at least 18 years old. The individual with ...

Survey: How has the COVID-19 Pandemic Impacted Fragile X Families

Researchers at Teachers College at Columbia University are conducting a survey to learn about the impact that the COVID-19 pandemic has had on multiple aspects of the lives of people with Fragile X Syndrome. We want to see how the Fragile X community specifically was impacted so that we can have a more focused plan of action for helping these families. The overall goal of this survey is to distribute our findings to medical professionals so that they can see what gaps have been created in their practices from the pandemic. 

Parents and Caregivers of Adults with Fragile X Syndrome Needed for a Survey

Kaylynn Shuleski, a master’s in genetic counseling candidate, is conducting a research study to explore the concerns and challenges caregivers may face when planning long-term supports and living arrangements for their adult children with Fragile X syndrome (FXS). This information will be valuable for current and future families when considering long-term supports, as well as for healthcare professionals, counselors, and policy makers.  About the Study Who can participate? Parents and caregivers of adults with full mutation ...